Gemcitabine combined with paclitaxel or paclitaxel/trastuzumab in metastatic breast cancer.

[1]  J. Garcia-conde,et al.  Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  G. Sledge.  Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. , 2001, Oncology.

[3]  M. Blackstein,et al.  Gemcitabine as First-Line Therapy in Patients with Metastatic Breast Cancer: A Phase II Trial , 2002, Oncology.

[4]  A. Murad,et al.  Phase II Trial of the Use of Paclitaxel and Gemcitabine as a Salvage Treatment in Metastatic Breast Cancer , 2001, American journal of clinical oncology.

[5]  M. Espié,et al.  Single-Agent Gemcitabine Is Active in Previously Treated Metastatic Breast Cancer , 2001, Oncology.

[6]  A. Murad,et al.  Rationale and dose-finding studies of the combination of irinotecan and a taxane on a weekly schedule. , 2001 .

[7]  K. Possinger,et al.  Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. , 1999, Anti-cancer drugs.

[8]  T. Fleming,et al.  Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial , 1998 .

[9]  L. Einhorn,et al.  A phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory solid tumors , 1997 .

[10]  A. Harris,et al.  Advanced breast cancer: a phase II trial with gemcitabine. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Hudis,et al.  Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  C. Hudis,et al.  Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G. Hortobagyi,et al.  The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. , 1993, Journal of the National Cancer Institute. Monographs.